Immune checkpoint inhibition in ovarian cancer

International Immunology

Volumn 28, Issue 7, 2016, Pages 339-348

  Hamanishi, Junzo ^a   Mandai, Masaki ^b   Konishi, Ikuo ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY   (Japan)

Author keywords

Biomarker; CTLA 4; Immunotherapy; PD 1; PD L1

Indexed keywords

ANTINEOPLASTIC AGENT; AVELUMAB; BMS 936559; CANCER VACCINE; CD3 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNE CHECKPOINT INHIBITOR; IPILIMUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TICILIMUMAB; UNCLASSIFIED DRUG; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 RECEPTOR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNE STATUS; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SIGNAL TRANSDUCTION; SURVIVAL RATE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; ANIMAL; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; OVARY TUMOR; PRECLINICAL STUDY; PROCEDURES; TREATMENT OUTCOME; TUMOR ESCAPE;

ANIMALS; ANTIBODIES, MONOCLONAL; B7-H1 ANTIGEN; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; OVARIAN NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME; TUMOR ESCAPE;

EID: 84977134531     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxw020     Document Type: Article

References (96)

1. Siegel, R. L., Miller, K. D. and Jemal, A. 2016. Cancer statistics, 2016. CA Cancer J. Clin. 66:7.
2. Available at: http://www.nccn.org/guidelines/ovarian/
3. Oza, A. M., Cook, A. D., Pfisterer, J. et al. 2015. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase randomised trial. Lancet Oncol. 16:928.
4. Aghajanian, C., Goff, B., Nycum, L. R. et al. 2015. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinumsensitive recurrent ovarian cancer. Gynecol. Oncol. 139:10.
5. Poveda, A. M., Selle, F., Hilpert, F. et al. 2015. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized Phase III AURELIA trial. J. Clin. Oncol. 33:3836.
6. Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K. et al. 2015. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 33:244.
7. Pignata, S., Lorusso, D., Scambia, G. et al. 2014. MITO-11: a randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or -refractory advanced ovarian cancer (AOC). J. Clin. Oncol. 32(Suppl.): Abstract no. 5503.
8. Ledermann, J., Perren, T. J., Raja, F. A. et al. 2013. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6. Proceedings of the 13th Annual European Cancer Congress, September 27- October 1, 2013. ESMO, Amsterdam, the Netherlands. Abstract no. 10.
9. Macfarlane Burnet, F. 1970. Immunological Surveillance. Pergamon Press, Oxford, UK.
10. Dunn, G. P., Bruce, A. T., Ikeda, H. et al. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3:991.
11. Zou, W. and Chen, L. 2008. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8:467.
12. Keir, M. E., Butte, M. J., Freeman, G. J. et al. 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26:677.
13. Topalian, S. L., Hodi, F. S., Brahmer, J. R. et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366:2443.
14. Robert, C., Long, G. V., Brady, B. et al. 2015. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372:320.
15. Robert, C., Schachter, J., Long, G. V. et al. 2015. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372:2521.
16. Borghaei, H., Paz-Ares, L., Horn, L. et al. 2015. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373:1627.
17. Hamanishi, J., Mandai, M., Ikeda, T. et al. 2015. Efficacy and safety of anti-PD-1 antibody in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33:4015.
18. Brahmer, J. R., Tykodi, S. S., Chow, L. Q. et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366:2455.
19. Varga, A., Piha-Paul, S. A., Ott, P. A. et al. 2015. Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: interim results from a phase Ib study. J. Clin. Oncol. 33(Suppl.): Abstract no. 5510.
20. Disis, M. L., Patel, M. R., Pant, S. et al. 2015. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: a phase Ib, open-label expansion trial. J. Clin. Oncol. 33(Suppl.): Abstract no. 5509.
21. Homicsko, K. and Coukos, G. 2015. Targeting programmed cell death 1 in ovarian cancer. J. Clin. Oncol. 33:3987.
22. Coleman, R. L. 2016. Ovarian cancer in 2015: insights into strategies for optimizing ovarian cancer care. Nat. Rev. Clin. Oncol. 13:71.
23. Ioannides, C. G., Freedman, R. S., Platsoucas, C. D. et al. 1991. Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J. Immunol. 146:1700.
24. Zhang, L., Conejo-Garcia, J. R., Katsaros, D. et al. 2003. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348:203.
25. Hamanishi, J., Mandai, M., Iwasaki, M. et al. 2007. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl Acad. Sci. USA 104:3360.
26. Hwang, W. T., Adams, S. F., Tahirovic, E. et al. 2012. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a metaanalysis. Gynecol. Oncol. 124:192.
27. Cancer Genome Atlas Research Network. 2011. Integrated genomic analyses of ovarian carcinoma. Nature 474:609.
28. Verhaak, R. G., Tamayo, P., Yang, J. Y. et al. 2013.Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J. Clin. Invest. 123:517.
29. Garcia-Lora, A., Algarra, I. and Garrido, F. 2003. MHC class I antigens, immune surveillance, and tumor immune escape. J. Cell Physiol. 195:346.
30. Massagué, J. 2008. TGFbeta in cancer. Cell 134:215.
31. Löb, S., Königsrainer, A. Rammensee, H. G. et al. 2009. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat. Rev. Cancer 9:445.
32. Li, S., Miner, K., Fannin, R. et al. 2004. Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium. Gynecol. Oncol. 92:622.
33. Bayry, J. 2009. Autoimmunity: CTLA-4: a key protein in autoimmunity. Nat. Rev. Rheumatol. 5:244.
34. Brunet, J. F., Denizot, F., Luciani, M. F. et al. 1987. A new member of the immunoglobulin superfamily-CTLA-4. Nature 328:267.
35. Blank, C. U. 2014. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. Curr. Opin. Oncol. 26:204.
36. Krummel, M. F. and Allison, J. P. 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182:459.
37. Peggs, K. S., Quezada, S. A., Chambers, C. A. et al. 2009. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206:1717.
38. Hodi, F. S., O'Day, S. J., McDermott, D. F. et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:711.
39. Calabrò, L., Morra, A., Fonsatti, E. et al. 2015. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapyresistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir. Med. 3:301.
40. Available at: https://clinicaltrials.gov/ct2/results?term=tremelimumab&Search=Search
41. Hodi, F. S., Mihm, M. C., Soiffer, R. J. et al. 2003. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA 100:4712.
42. Hodi, F. S., Butler, M., Oble, D. A. et al. 2008. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyteassociated antigen 4 in previously vaccinated cancer patients. Proc. Natl Acad. Sci. USA 105:3005.
43. Available at: https://clinicaltrials.gov/ct2/show/NCT01611558
44. Ribas, A., Kefford, R., Marshall, M. A. et al. 2013. Phase III randomized clinical trial comparing tremelimumab with standard-ofcare chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31:616.
45. Callahan, M. K., Ott, P. A., Odunsi, K. et al. 2014. A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors. J. Clin. Oncol. 32(Suppl.): Abstract no. TPS3120.
46. Ishida, Y., Agata, Y., Shibahara, K. and Honjo, T. 1992. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11:3887.
47. Greenwald, R. J., Freeman, G. J., Sharpe, A. H. 2005. The B7 family revisited. Annu. Rev. Immunol. 23:515.
48. Okazaki, T. and Honjo, T. 2007. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19:813.
49. Iwai, Y., Ishida, M., Tanaka, Y. et al. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99:12293.
50. Iwai, Y., Terawaki, S. and Honjo, T. 2005. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 17:133.
51. Dong, H., Strome, S. E., Salomao, D. R. et al. 2002. Tumorassociated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8:793.
52. Hirano, F., Kaneko, K., Tamura, H. et al. 2005. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65:1089.
53. Curiel, T. J., Wei, S., Dong, H. et al. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9:562.
54. Sharma, M. D., Baban, B., Chandler, P. et al. 2007. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117:2570.
55. Peng, J., Hamanishi, J., Matsumura, N. et al. 2015. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-?B to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res. 75:5034.
56. Abiko, K., Mandai, M., Hamanishi, J. et al. 2013. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin. Cancer Res. 19:1363.
57. Thompson, R. H., Gillett, M. D., Cheville, J. C. et al. 2004. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl Acad. Sci. USA 101:17174.
58. Ohigashi, Y., Sho, M., Yamada, Y. et al. 2005. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res. 11:2947.
59. Nomi, T., Sho, M., Akahori, T. et al. 2007. Clinical significance and therapeutic potential of the programmed death-1 ligand/ programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 13:2151.
60. Konishi, J., Yamazaki, K., Azuma, M. et al. 2004. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin. Cancer Res. 10:5094.
61. Wu, C., Zhu, Y., Jiang, J. et al. 2006. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 108:19.
62. Ghebeh, H., Mohammed, S., Al-Omair, A. et al. 2006. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8:190.
63. Ahmadzadeh, M., Johnson, L. A., Heemskerk, B. et al. 2009. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114:1537.
64. Hamanishi, J., Mandai, M., Abiko, K. et al. 2011. The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin. Immunol. 141:338.
65. Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P. et al. 2010. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl Acad. Sci. USA 107:7875.
66. Krempski, J., Karyampudi, L., Behrens, M. D. et al. 2011. Tumorinfiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J. Immunol. 186:6905.
67. Liu, Y., Yu, Y., Yang, S. et al. 2009. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol. Immunother. 58:687.
68. Brahmer, J. R., Drake, C. G., Wollner, I. et al. 2010. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28:3167.
69. Topalian, S. L., Sznol, M., McDermott, D. F. et al. 2014. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32:1020.
70. Hamanishi, J., Mandai, M., Matsumura, N. et al. 2016. PD-1/ PD-L1 blockade in cancer treatment: perspectives and issues. Int. J. Clin. Oncol. February 22, 2016, Epub ahead of print.
71. Available at: http://rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153004
72. Herbst, R. S., Soria, J. C., Kowanetz, M. et al. 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563.
73. Powles, T., Eder, J. P., Fine, G. D. et al. 2014. MPDL3280A (anti- PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558.
74. Brahmer, J., Reckamp, K. L., Baas, P. et al. 2015. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373:123.
75. Larkin, J., Chiarion-Sileni, V., Gonzalez, R. et al. 2015. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373:23.
76. Taube, J. M., Anders, R. A., Young, G. D. et al. 2012. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4:127ra37.
77. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C. et al. 2013. Signatures of mutational processes in human cancer. Nature 500:415.
78. Postow, M. A., Callahan, M. K., Wolchok, J. D. 2015. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33:1974.
79. Snyder, A., Makarov, V., Merghoub, T. et al. 2014. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371:2189.
80. Rizvi, N. A., Hellmann, M. D., Snyder, A. et al. 2015. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124.
81. Le, D. T., Uram, J. N., Wang, H. et al. 2015. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372:2509.
82. Vétizou, M., Pitt, J. M., Daillère, R. et al. 2015. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350:1079.
83. Sivan, A., Corrales, L., Hubert, N. et al. 2015. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti- PD-L1 efficacy. Science 350:1084.
84. Strickland, K., Howitt, B. E., Rodig, S. J., et al. 2015. Tumor infiltrating and peritumoral T cells and expression of PD-L1 in BRCA1/2-mutated high grade serous ovarian cancers. J. Clin. Oncol. 33(Suppl.): Abstract no. 5512.
85. Coffelt, S. B. and de Visser, K. E. 2015. Immune-mediated mechanisms influencing the efficacy of anticancer therapies. Trends Immunol. 36:198.
86. Sunshine, J. and Taube, J. M. 2015. PD-1/PD-L1 inhibitors. Curr. Opin. Pharmacol. 23:32.
87. Chinai, J. M., Janakiram, M., Chen, F. et al. 2015. New immunotherapies targeting the PD-1 pathway. Trends Pharmacol. Sci. 36:587.
88. Larkin, J., Chiarion-Sileni, V., Gonzalez, R. et al. 2015. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373:23.
89. Clinical Trials. gov. NCT02498600. 2015. Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. National Institutes of Health, Bethesda, Maryland.
90. Wei, H., Zhao, L., Li, W. et al. 2013. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS One 8:e84927.
91. Lu, L., Xu, X., Zhang, B. et al. 2014. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J. Transl. Med. 12:36.
92. Naidoo, J., Page, D. B., Li, B. T. et al. 2015. Toxicities of the anti- PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 26:2375.
93. Champiat, S., Lambotte, O., Barreau, E. et al. 2016. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann. Oncol. 27:559.
94. Postow, M. A. 2015. Managing Immunotherapy-Related Side Effects. ASCO Annual Meeting, May 29 to June 2. The ABCs of Cancer Immunotherapy, Chicago, Illinois.
95. Young, R. C. 2015. Value-based cancer care. N. Engl. J. Med. 373:2593.
96. Schnipper, L. E., Davidson, N. E., Wollins, D. S. et al. 2015. American Society of Clinical Oncology Statement: A conceptual framework to assess the value of cancer treatment options. J. Clin. Oncol. 33:2563.